

IPW

C#	M#
1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100

TC/A.U.

Examiner:

Date: October 27, 2004

A circular black ink stamp from the Office of Intellectual Property (OIP). The text "OIP" is at the top, "JC25" is at the top right, "OCT 27 2004" is in the center, and "PATENT & TRADEMARK OFFICE" is at the bottom.

Sir:

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Independent claims after amendment	0	minus highest number		
previously paid for	3	(at least 3) =	0	x \$ 86.00
				\$ 0.00

If proper multiple dependent claims now added for first time, add \$290.00 (ignore improper)	\$	0.00
----------------------------------------------------------------------------------------------	----	------

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$420.00/2 months; \$950.00/3 months) \$ 0.00

Terminal disclaimer enclosed, add \$ 110.00	\$	0.00
---------------------------------------------	----	------

<input type="checkbox"/> First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$770.00)	\$	0.00
---------------------------------------------------------------------------------------------------------------	----	------

☐ Please enter the previously unentered _____, filed _____

☐ Submission attached

Subtotal \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract	- \$	0.00
-------------------------------------------------------------------	------	------

☐ Applicant claims "small entity" status. ☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$180.00)	\$	0.00
----------------------------------------------------------------	----	------

Assignment Recording Fee (\$40.00)	\$	0.00
------------------------------------	----	------

Other:	0.00
--------	------

TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

NIXON & VANDERHYE P.C.

By Atty: Mary J. Wilson, Reg. No. 32,955

Signature:

Mary L. Wilson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Patent Application of

HAYNES et al

Serial No. 10/753,339

Filed: January 9, 2004

For: HUMAN IMMUNODEFICIENCY VIRUS VACCINE

Confirmation No. 7106

Atty. Ref.: 1579-880

Group:

Examiner:

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

October 27, 2004

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
 - ☐ a) The required Statement made in item 8 below; or
 - ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
 - ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
 - ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
 - ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
 - ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

HAYNES et al
Serial No. 10/753,339
October 27, 2004

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: Mary J. Wilson
Mary J. Wilson
Reg. No. 32,955

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE
CITATION**

(Use several sheets if necessary)



ATTY. DOCKET NO.

1579-880

SERIAL NO.

10/753,339

APPLICANT

HAYNES et al

FILING DATE

GROUP

January 9, 2004

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,976,551	11/1999	Mottez et al			
	6,656,471	12/2003	Sastry et al			

FOREIGN PATENT DOCUMENTS

							TRANSLATION	
DOCUMENT			DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
		WO 91/04051	4/1991	WIPO				
		WO 00/52040	9/2000	WIPO				
		WO 02/20555	3/2002	WIPO				
		WO 02/069691	9/2002	WIPO				
		WO 01/43693	6/2001	WIPO				
		WO 01/54719	8/2001	WIPO				
		WO 96/41189	12/1996	WIPO				
		EP 0 693 938 B1	1/1996	Europe				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Novitsky et al, "Identification of Human Immunodeficiency Virus Type 1 Subtype C Gag-, Tat-, Rev-, and Nef-Specific Elispot-Based Cytotoxic T-Lymphocyte Responses for AIDS Vaccine Design", Journal of Virology 75(19):9210-9228 (2001)
	Wilson et al, "Identification and Antigenicity of Broadly Cross-Reactive and Conserved Human Immunodeficiency Virus Type 1-Derived Helper T-Lymphocyte Epitopes", Journal of Virology 75(9):4195-4207 (2001)
	Hinkula et al, "Epitope Mapping of the HIV-1 gag Region with Monoclonal Antibodies", Molecular Immunology 27(5):395-403 (1990)
	Michel et al, "HIV-1 Env, Nef, and Gag-specific T-Cell Immunity in Mice: Conserved Epitopes in NefP27 and Gag P25 Proteins", AIDS Research and Human Retroviruses 8(4):469-478 (1992)
	Mills et al, "HIV p24-specific Helper T Cell Clones from Immunized Primates Recognize Highly Conserved Regions of HIV-1", J. Immunol. 144:1677-1683 (1990)
	Nixon et al, "HIV-1 gag-specific Cytotoxic T Lymphocytes Defined with Recombinant Vaccinia Virus and Synthetic Peptides", Nature 336:484-487 (1988)
	Baier et al, "HIV Suppression by Interleukin-16", Nature 378:563 (1995)
	Goulder et al, "Novel, Cross-Restricted, Conserved, and Immunodominant Cytotoxic T Lymphocyte Epitopes in Slow Progressors in HIV Type I Infection", AIDS Research and Human Retroviruses 12(18):1691-1698 (1996)
	Hale et al, "T Cell Multideterminant Regions in the Human Immunodeficiency Virus Envelope: Toward Overcoming the Problem of Major Histocompatibility Complex Restriction", International Immunology 1(4):409-415 (1989)
	Loktev et al, "Design of immunogens as components of a new generation of molecular vaccines", Journal of Biotechnology 44(1):129-137 (1996)

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)